tiprankstipranks
InMed Pharmaceuticals (INM)
NASDAQ:INM
Holding INM?
Track your performance easily

InMed Pharmaceuticals (INM) Stock Price & Analysis

334 Followers

INM Stock Chart & Stats


Financials

Annual

Ownership Overview

53.42%41.27%
53.42% Insiders
― Other Institutional Investors
41.27% Public Companies and Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

INM FAQ

What was InMed Pharmaceuticals’s price range in the past 12 months?
InMed Pharmaceuticals lowest stock price was $2.41 and its highest was $15.69 in the past 12 months.
    What is InMed Pharmaceuticals’s market cap?
    InMed Pharmaceuticals’s market cap is $3.26M.
      When is InMed Pharmaceuticals’s upcoming earnings report date?
      InMed Pharmaceuticals’s upcoming earnings report date is Feb 18, 2025 which is in 30 days.
        How were InMed Pharmaceuticals’s earnings last quarter?
        Currently, no data Available
        Is InMed Pharmaceuticals overvalued?
        According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does InMed Pharmaceuticals pay dividends?
          InMed Pharmaceuticals does not currently pay dividends.
          What is InMed Pharmaceuticals’s EPS estimate?
          InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does InMed Pharmaceuticals have?
          InMed Pharmaceuticals has 724,152 shares outstanding.
            What happened to InMed Pharmaceuticals’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of InMed Pharmaceuticals?
            Currently, no hedge funds are holding shares in INM
            ---

            Company Description

            InMed Pharmaceuticals

            InMed Pharmaceuticals, Inc. engages in the research and development of cannabinoid-based therapies and biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. It offers pipeline of medications that target diseases with unmet medical needs, such as epidermolysis bullosa, glaucoma, and orofacial pain. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            AXIM Biotechnologies
            Corbus Pharmaceuticals
            Outlook Therapeutics
            Sorrento Therapeutics
            Bausch Health Companies
            Pfizer
            Popular Stocks
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis